http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2750642-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_567b1e0c9d5905537fc43cabba955532 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1716 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-12 |
| filingDate | 2018-09-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_68c00dd1c91d4419c278e0070c6ee259 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_26c2fd1addba0260f9dadee50e13e010 |
| publicationDate | 2020-03-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2750642-A1 |
| titleOfInvention | Pharmaceutical composition comprising serum amyloid P protein to treat acute or chronic kidney failure |
| abstract | Drugs containing serum amyloid P protein to prevent the development of fibrosis. The invention relates to a sterile aqueous solution for peritoneal dialysis comprising serum amyloid P protein, electrolytes and one or more osmotic agents for the treatment of patients with renal failure undergoing peritoneal dialysis. In this way, the solution fulfills the function of dialysis solutions, in addition to reducing the ultrafiltration deficit and the deterioration of the peritoneal membrane caused by exposure to dialysis solutions. |
| priorityDate | 2018-09-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 52.